Measurable Residual Disease for AML by Flow Cytometry (Pilot -Not Accredited)


The measurement of Measurable Residual Disease (MRD) populations is often performed following treatment for leukaemic disorders. The levels of MRD are used as a predictive factor for relapse and as an indicator for patients entering remission. As such the measurement of MRD can have a direct effect on the treatment regimen of a patient.


The Measurable Residual Disease in AML programme will issue up to four send outs per financial year.  Each send out will include a reference sample and two follow up samples of a known AML case post treatment at different time points.


Participants will be asked to quantify the level of residual disease in the follow up samples. If you wish to be involved in the study please contact 


 ***NEW IN 2022-2023*** The Minimal Residual Disease Programmes have been renamed in line with current naming conventions and will now be called Measurable Residual Disease Programmes. All other aspects of the programme operation will remain unchanged.


No activities in relation to this EQA programme are subcontracted.



To register for this programme, please click here.

Example Measurable Residual Disease for AML by Flow Cytometry (Not Accredited) Report
To view the annotations on this report, please download the PDF and view in a PDF reader such as Adobe Acrobat.
MRD AML Example Report.pdf
Adobe Acrobat document [1.3 MB]
Print Print | Sitemap

Follow Us Online
Facebook Twitter LinkedIn Youtube


Last updated 15/12/2021 © UK NEQAS for Leucocyte Immunophenotyping not to be reproduced in all or part without permission.

This website uses cookies. For more information please click here.

Please click here for our privacy policy.

The UK NEQAS Organisation is a Company Limited by Guarantee (No.3012351) and a Registered UK Charity (No.1044013).